FDA Approves Secukinumab for Adolescent Hidradenitis Suppurativa
The FDA’s approval of a new weight-based secukinumab (Cosentyx) formulation offers adolescents with moderate-to-severe hidradenitis suppurativa (HS) a new treatment option for the condition, also known as acne inversa. A chronic inflammatory skin disease






